Legal & General Group’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.6K | Sell |
9,895
-5,579
| -36% | -$16.5K | ﹤0.01% | 3020 |
|
|
2026
Q1 | $47.5K | Sell |
15,474
-71,426
| -82% | -$309K | ﹤0.01% | 2687 |
|
|
2025
Q4 | $310K | Buy |
86,900
+35
| +0% | +$214 | ﹤0.01% | 2527 |
|
|
2025
Q3 | $773K | Sell |
86,865
-107
| -0.1% | -$1.08K | ﹤0.01% | 2314 |
|
|
2025
Q2 | $802K | Buy |
86,972
+13,886
| +19% | +$119K | ﹤0.01% | 2297 |
|
|
2025
Q1 | $627K | Buy |
73,086
+65,781
| +900% | +$621K | ﹤0.01% | 2332 |
|
|
2024
Q4 | $78.5K | Sell |
7,305
-67
| -0.9% | -$515 | ﹤0.01% | 2741 |
|
|
2024
Q3 | $41.9K | Buy |
7,372
+772
| +12% | +$4.45K | ﹤0.01% | 2818 |
|
|
2024
Q2 | $27.9K | Sell |
6,600
-64,487
| -91% | -$261K | ﹤0.01% | 2895 |
|
|
2024
Q1 | $362K | Sell |
71,087
-186
| -0.3% | -$1.05K | ﹤0.01% | 2552 |
|
|
2023
Q4 | $664K | Sell |
71,273
-201
| -0.3% | -$1.38K | ﹤0.01% | 2352 |
|
|
2023
Q3 | $468K | Buy |
71,474
+828
| +1% | +$6.59K | ﹤0.01% | 2467 |
|
|
2023
Q2 | $574K | Buy |
70,646
+32,706
| +86% | +$280K | ﹤0.01% | 2419 |
|
|
2023
Q1 | $325K | Buy |
37,940
+1,790
| +5% | +$17.9K | ﹤0.01% | 2433 |
|
|
2022
Q4 | $335K | Buy |
36,150
+1,111
| +3% | +$11.9K | ﹤0.01% | 2431 |
|
|
2022
Q3 | $362K | Buy |
35,039
+1,483
| +4% | +$15.7K | ﹤0.01% | 2424 |
|
|
2022
Q2 | $336K | Buy |
33,556
+1,737
| +5% | +$16.5K | ﹤0.01% | 2455 |
|
|
2022
Q1 | $392K | Buy |
31,819
+612
| +2% | +$7.53K | ﹤0.01% | 2459 |
|
|
2021
Q4 | $541K | Buy |
31,207
+1,201
| +4% | +$22.8K | ﹤0.01% | 2386 |
|
|
2021
Q3 | $538K | Buy |
30,006
+19,940
| +198% | +$397K | ﹤0.01% | 2395 |
|
|
2021
Q2 | $231K | Buy |
10,066
+3,658
| +57% | +$54.2K | ﹤0.01% | 2499 |
|
|
2021
Q1 | $96K | Buy |
6,408
+158
| +3% | +$1.73K | ﹤0.01% | 2633 |
|
|
2020
Q4 | $34K | Sell |
6,250
-167
| -3% | -$880 | ﹤0.01% | 2902 |
|
|
2020
Q3 | $29K | Sell |
6,417
-1,891
| -23% | -$8.14K | ﹤0.01% | 2853 |
|
|
2020
Q2 | $41K | Buy |
8,308
+388
| +5% | +$1.47K | ﹤0.01% | 2779 |
|
|
2020
Q1 | $25K | Sell |
7,920
-768
| -9% | -$2.68K | ﹤0.01% | 2823 |
|
|
2019
Q4 | $22K | Buy |
8,688
+1,520
| +21% | +$3.99K | ﹤0.01% | 3149 |
|
|
2019
Q3 | $23K | Hold |
7,168
| – | – | ﹤0.01% | 3080 |
|
|
2019
Q2 | $24K | Buy |
+7,168
| New | +$22.3K | ﹤0.01% | 3120 |
|
|
2018
Q2 | – | Sell |
-5,773
| Closed | -$16K | – | 3355 |
|
|
2018
Q1 | $16K | Hold |
5,773
| – | – | ﹤0.01% | 3145 |
|
|
2017
Q4 | $19K | Sell |
5,773
-2,439
| -30% | -$9.6K | ﹤0.01% | 3150 |
|
|
2017
Q3 | $34K | Buy |
8,212
+3,652
| +80% | +$16.2K | ﹤0.01% | 3031 |
|
|
2017
Q2 | $24K | Hold |
4,560
| – | – | ﹤0.01% | 3112 |
|
|
2017
Q1 | $26K | Sell |
4,560
-1,388
| -23% | -$7.17K | ﹤0.01% | 3011 |
|
|
2016
Q4 | $24K | Buy |
+5,948
| New | +$21.2K | ﹤0.01% | 3087 |
|
Other funds holding AVXL
SF
Legal & General Group's AVXL Position: Q2 2026 in Review
Legal & General Group reduced its Anavex Life Sciences (AVXL) stake by 36% in Q2 2026, selling an estimated $16.5K and leaving 9,895 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3020.
Legal & General Group first reported a position in AVXL in Q4 2016 and has held it in 35 quarters since. The position peaked at $802K in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.
- Legal & General Group held 9,895 shares of Anavex Life Sciences worth $25.6K as of Q2 2026.
- Legal & General Group sold 5,579 Anavex Life Sciences shares in Q2 2026, an estimated $16.5K.
- Anavex Life Sciences made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3020 holding.
- Legal & General Group first reported a position in Anavex Life Sciences in Q4 2016 and has held it in 35 quarters since.
- Legal & General Group's Anavex Life Sciences position peaked at $802K in Q2 2025.
- 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.